2. All plaintiffs' claims are dismissed.

3. The plaintiffs' total costs of litigation.

A. The status, etc. (No. 1, 2, and 17 Evidence) 1 of the parties to the case (hereinafter “Plaintiff Health”) (hereinafter “Plaintiff”) is the company that develops, manufactures, and sells the drugs, and is each patentee of the instant 1 and 2 inventions, and Plaintiff C Health Care Co., Ltd. (hereinafter “Plaintiff C Health Care”) is the exclusive licensee granted an exclusive license for manufacturing, using, and selling the patented invention of this case No. 1 and 2 from Plaintiff Health. Meanwhile, the Defendant is a company engaged in the manufacturing of drugs, etc., and manufactures a drug listed in the attached list of medicines (hereinafter “Defendant drug”) under the name of “Monono No. 1 and 2”. Meanwhile, the Defendant is a company that manufactures pharmaceutical products, etc., and manufactures a drug listed in the attached list of medicines (hereinafter “Defendant drug”).

B. The title of the invention of this case (No. 1, 4, 18, 20, 39) 1: Pallonlon's "Palonononn" is written in the patented invention of this case in Korean language, or is written in accordance with desirable external language marking techniques; hereinafter referred to as "Palonnonn theory". The liquid pharmaceutical pharmaceutical pharmaceutical product 2)/ the date of international filing date/date of priority claim/ translation/Korean translation/registration number: The chemical compound of this case (No. 11304, Jul. 29, 2005; hereinafter "No. 30, 2000, hereinafter referred to as "No. 130, 400, 1000, 2000, 2000, 2000, 300,000, 200, 200, 200, 200, 30,000,000

It is used in the separation, refining, analysis, etc. of metal salt, and it is also widely used as a detailed agents, stabilizing agents, and stalking system.

In particular, specified.